Why genetic and biomarker testing matters more than ever in cancer care
Cancer treatment is increasingly shaped by what a tumor looks like at the molecular level, not just by where it started. That is why genetic and biomarker testing now plays a central role in many oncology decisions. In practical terms, these tests help clinicians understand whether a cancer may respond to a targeted drug, whether immunotherapy is likely to help, and whether inherited risk should be discussed with family members.
If you are new to the topic, the most helpful place to start is the distinction between tumor testing and inherited testing. The National Cancer Institute explains that tumor testing looks for changes in the cancer itself, while inherited testing looks for changes passed through families. Those are related ideas, but they answer different questions and are used in different ways.
For a plain-language overview, the NCI’s page on biomarker testing for cancer treatment is one of the clearest starting points. ASCO also provides useful guidance on how somatic and germline testing fit into modern oncology care, especially when a result may affect treatment selection or family counseling. For readers who want the regulatory angle, the FDA’s page on companion diagnostics explains why some tests are specifically tied to approved therapies.
Tumor testing vs. inherited testing
It helps to keep the two main kinds of genetic testing separate:
- Tumor (somatic) testing looks at the cancer cells themselves and searches for changes that may help match a treatment.
- Inherited (germline) testing looks for variants a person was born with and may help estimate cancer risk for that person and their relatives.
That distinction matters. A tumor result does not automatically mean a family member has the same change. And an inherited result does not always tell a clinician what a tumor will do today. In oncology, the question is usually not “Does this test say everything?” but “What does this test help us know next?”
How biomarker testing guides treatment
Biomarker testing can help identify patients who are more likely to benefit from certain targeted therapies or immunotherapies. In some cancers, the test may influence whether a drug is used at all. In others, it may help refine the order of treatment options or support a clinical trial discussion.
This is one reason the topic matters so much now. The field is moving toward more precise decision-making, and the evidence base keeps growing. The FDA’s list of authorized companion diagnostic devices shows how widely these tests are being used across oncology. That does not mean every patient needs every test. It does mean testing is no longer a niche add-on in many cancer pathways.
In hematologic cancers, biomarker results can be especially important because treatment often depends on specific disease features. In solid tumors, testing may be used to look for markers linked to targeted drugs, immunotherapy response, or trial eligibility. The exact panel and timing vary by diagnosis, stage, and prior treatment history.
Where liquid biopsy and ctDNA fit
Liquid biopsy has made cancer testing feel more flexible, but it is still a tool with limits. In a liquid biopsy, clinicians look for tumor material in blood, often including circulating tumor DNA, or ctDNA. This can be useful when tissue is hard to obtain, when a tumor may have changed over time, or when doctors want to monitor disease dynamics.
That said, a blood-based test is not always a full substitute for tissue testing. Sometimes the best answer still comes from a tissue sample, and sometimes both approaches are used together. The practical takeaway is simple: liquid biopsy can add valuable information, but it should be interpreted in context, not treated like a magic shortcut. Medicine rarely gives us shortcuts without a small print section.
Why companion diagnostics matter
A companion diagnostic is a test used to help identify whether a patient is likely to benefit from a specific therapy or whether a therapy should be avoided. That link between test and treatment is important because it ties the lab result to a clinical decision, not just to curiosity.
The FDA explains that companion diagnostics are part of the pathway for some approved cancer medicines. This is especially relevant when a drug is approved for patients whose tumors carry a particular marker. The test and treatment are designed to work together as a decision pair.
Cancers where testing is especially important
Testing is often discussed early in cancers such as lung cancer, breast cancer, colorectal cancer, ovarian cancer, melanoma, and several blood cancers. In those settings, molecular information may influence first-line treatment choices, later treatment lines, or whether a patient should be referred for genetic counseling.
That said, the right test depends on the cancer type. A broad panel may be useful in one situation and unnecessary in another. This is why specialist interpretation matters. The result is only useful if it is read in the context of the diagnosis, the pathology report, and the patient’s treatment goals.
Questions to ask before and after testing
If you are preparing for testing, a few practical questions can make the conversation easier:
- Is this tumor testing, inherited testing, or both?
- What will this test help decide?
- Will the sample come from tissue, blood, or another source?
- How long will results take?
- Could the result affect treatment, trial options, or family counseling?
- What happens if the result is unclear or negative?
- Will I need a genetic counselor or another specialist?
Those questions are modest, but they are useful. They help keep the conversation focused on decisions rather than jargon.
Limits, privacy, and interpretation
Genetic and biomarker testing can be very helpful, but it does not answer every question. A negative result does not always rule out a clinically important change. A positive result does not always mean there is a matched treatment available. And a result that seems promising on paper still needs clinical judgment before it becomes a treatment plan.
Privacy also matters. The NCI’s genetic testing fact sheet offers a good overview of how results may be shared, what they can mean for family members, and why patients should ask how their information will be handled. The safest next step is usually to review the result with the oncology team or a genetics professional, not to try to decode it alone between appointments.
Takeaway
Genetic and biomarker testing is now part of routine cancer decision-making in many settings. It does not guarantee a treatment change, and it does not replace careful clinical care. But when used well, it can help patients and clinicians make smarter, more specific choices about therapy, follow-up, and family risk discussions.
For readers exploring the site more broadly, you may also find the Latest Lectures and Congress sections useful, along with our About and Contact pages if you want to learn more or reach out.
Related reading: Quantitative PCR Results Remain Questionable: The Need for the MIQE Guidelines